|
KMID : 0377619740270020145
|
|
Korean Jungang Medical Journal
1974 Volume.27 No. 2 p.145 ~ p.150
|
|
|
The Clinical Experience of Danzen, a New Proteolytic Enzyme
|
|
김인철/Kim, I.C.
주상용/안긍섭/고용복/이용각/Joo, S.Y./Ahn, K.S./Koh, Y.B./Lee, Y.K.
|
|
|
Abstract
|
|
|
The so called protease constitutes the principal parts of enzymotherapy and trypsin, chymotrypsin, streptokinase, plasmin, ?pronase-P, and bromelain are widely used.
The basic activity of protease is to specifically split the molecular chain of protein. That is, it hydrolyzes abnormal proteins or from the clinical point of view, this may be described as (1) anti-inflammatory and anti-edematous activities, (2) necrotic tissue liquefying action, (3) anticoagulant activity, and (4) mucus liquefying activity.
The direct mechanism of action of protease has been known to be a process whereby an oral protease in absorbed, binds with its inhibitor and the balance between plasmin-inhibitor and plasmin is destroyed, transiently producing such a state where plasmin is dominant, and this causes a therapeutic effect in one way or another.
Danzen is a preparation of Serratio-peptidase, an anti-inflammatory oral enzyme, developed by the Research Laboratories of the Takeda Chemical Industries in Japan.
It is more potent in anti-inflammatory activity and anti-tumefacient effect than heretofore available anti-inflammatory enzymes and has less side effect.
We obtained the clinical experience of Danzen administered to 45 patients; inflammatory diseases 10 cases, swelling and hematoma after injury 8 cases, and postoperative swelling and hematoma 27 cases.
The results are as follows:
1) Danzen was effective in reducing the induration of lesions; inflammatory lesion after 5 days of administration, traumatic lesion in 3 days and operative wound in 3 days.
2) Danzen was effective in decreasing the elevated skin temperature of lesions; 3 days after administration in all cases.
3) No particular toxicity or side effect of Danzen was seen, except for mild indigestion in 2 cases.
4) The effective rates were 80% in inflammatory diseases, 87. 5% in swelling and hematoma after injury, and 81. 5% in postoperative swelling and hematoma.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|